Parkinsonian
Poster
Remotely acquired speech-based biomarkers and their relation to motor and cognitive functions in Parkinson’s disease
Alexander Jäck, Tabea Thies, Mira Fischer, Elisa Mallick, Lena Marth, Olivia Wagemann, Sonja Schönecker, Endy Weidinger, Urban Fietzek, Alexandra König, Nicklas Linz, Johannes Tröger, Günter Höglinger, Johannes Levin
*Presented at MDS Congress 2026
Objective
To evaluate the feasibility and clinical validity of remote, digital speech-based cognitive and speech motor assessments in Parkinson’s disease (PD).
Background
Speech in PD reflects both motor and cognitive impairment, offering a scalable source for digital biomarkers. While speech tasks can be collected remotely, evidence is needed that app-based assessments are feasible at home and yield measures that relate meaningfully to established clinical outcomes.
Methods
24 German-speaking individuals with PD were enrolled from the DESCRIBE study in Munich [table1]. Diagnosis followed the established MDS criteria [1]. Clinical assessment included part III of the Unified Parkinson’s Disease Rating Scale (total score, speech item), and the Montreal Cognitive Assessment (MoCA).
Participants completed one home-based session using the Mili mobile app, including speech-based cognitive tests (verbal fluency; verbal learning) and speech motor tasks (maximum vowel phonation, reading, free speech, oral diadochokinesis “pataka”). Speech samples were processed using SIGMA, ki:elements proprietary processing pipeline to derive speech-based cognitive (SB-C) total score and subscores for memory, processing speed, and executive functioning [2], and speech-based motor (SB-M) Intelligibility Score [3]. Additionally, selected SB-M single features were extracted and will be analyzed for conference presentation. Clinical validation involved Spearman correlations between SB-C and MoCA, and SB-M with UPDRS III and disease duration.
Results
Participant characteristics and averaged performance are reported [table 1, table 2]. SB-C total score correlated with MoCA (ρ=.496, p=.016). SB-C subscores showed significant associations for processing speed (ρ=.508, p=.013) and memory (ρ=.438, p=.037), and a trend for executive functions (ρ=.366, p=.086). SB-M Intelligibility correlated with UPDRS III total (ρ=−.475, p=.019) and showed trends with the UPDRS III speech item (ρ=−.371, p=.074), and disease duration (ρ=−.367, p=.077).
Conclusions
Remote, app-based speech assessment in PD is feasible and yields automated measures that align with clinical gold standards for motor and cognitive function. These findings support remotely acquired speech as a scalable digital biomarker approach for identification and monitoring PD severity in real-world settings.
